Contact Us
  • Choose License Type

The Global Pneumococcal Vaccines Market, by Vaccine Type (PCV10, PCV13, and PPSV23), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) was valued at US$ 7,376.6 million in 2018 and is projected to exhibit a CAGR of 7.5% over the forecast period (2018 - 2026).

 Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination For instance, in April 2016, Glaxo Smith Kline (GSK) and Vodafone collaborated to provide smartphones with an app to various healthcare facilities in northern Mozambique, Africa for a period of one year. The program received funds from GAVI and United States Agency for International Development (USAID) under mVacciNation pilot program. The app enables these healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, thereby improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination.

Browse 26 Market Data Tables and 32 Figures spread through 150 Pages and in-depth TOC on "Pneumococcal Vaccines Market, by Vaccine Type (PCV10, PCV13, and PPSV23), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Forecast to 2026"

To know the latest trends and insights related to pneumococcal vaccines market, click the link below:

https://www.coherentmarketinsights.com/market-insight/pneumococcal-vaccines-market-2295

Increasing collaborations among key players to develop and introduce new pneumococcal vaccines and ongoing clinical trial studies on pneumococcal vaccine are expected to drive growth of the pneumococcal vaccines market. For instance, in April 2018, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. Furthermore, in February 2017, Astellas Pharma Inc. and Affinivax, Inc. signed an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae. This partnership would utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) to develop a novel vaccine.

Key Takeaways of the Pneumococcal Vaccines Market:

  • The global pneumococcal vaccines market is expected to witness a CAGR of 7.5% during the forecast period, owing to increasing research and development activities to introduce novel vaccines.
  • Increasing adoption of PCV13 vaccine, especially for adult and pediatric indication, results in the vaccine’s increasing demand in various emerging economies. Therefore, this segment is expected to account for major revenue share in pneumococcal vaccines market over the forecast period. According to the United Nations Children's Fund (UNICEF), in 2016, around 74 million doses of PCV13 were supplied, with an increase by 7.5% as compared to 2015 globally (67 million doses).
  • Major players operating in the global pneumococcal vaccines market include, Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner